Fimasartan, Ketoconazole, Rifampicin
DrugFimasartan (1 day)
Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)
Rifampicin (9 days) Rifampicin + Fimasartan (1 day)
NCT Number: NCT00938262
To evaluate the effect of ketoconazole and rifampicin on the pharmacokinetics of fimasartan.
Looking for future studies?
Notify Me20 year–45 year
Male
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Fimasartan (1 day)
Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)
Rifampicin (9 days) Rifampicin + Fimasartan (1 day)
Time frame: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 32, (48, 56) h
Boryung Pharmaceutical Co., Ltd
Industry
An Open-label, Three-treatment, Three-period, One-sequence, Crossover Study to Evaluate the Effect of Ketoconazole and Rifampicin on the Pharmacokinetics of Fimasartan in Healthy Male Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07704697
Cardiovascular Diseases, Essential Hypertension
Beijing, Beijing Municipality, China
View Trial DetailsNCT07704684
Cardiovascular Diseases, Essential Hypertension
Beijing, Beijing Municipality, China
View Trial DetailsNCT07700875
Cardiovascular Diseases, Essential Hypertension
Jinan, Shangdong, China
View Trial DetailsNCT05503953
Cardiovascular Diseases, Essential Hypertension
Seoul, South Korea
View Trial Details